Citigroup’s Medicines Co MDCO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q1
Sell
-2,541,983
Closed -$216M 7966
2019
Q4
$216M Buy
2,541,983
+2,275,369
+853% +$152M 0.16% 117
2019
Q3
$13.3M Buy
266,614
+124,263
+87% +$4.96M 0.01% 1192
2019
Q2
$5.19M Buy
142,351
+139,092
+4,268% +$4.54M ﹤0.01% 1945
2019
Q1
$92K Sell
3,259
-104,343
-97% -$2.46M ﹤0.01% 5831
2018
Q4
$2.06M Buy
107,602
+54,135
+101% +$1.26M ﹤0.01% 2636
2018
Q3
$1.6M Sell
53,467
-270,733
-84% -$10.2M ﹤0.01% 2971
2018
Q2
$11.9M Buy
324,200
+314,534
+3,254% +$10.2M 0.01% 1156
2018
Q1
$318K Buy
9,666
+7,106
+278% +$222K ﹤0.01% 4465
2017
Q4
$70K Sell
2,560
-407
-14% -$12.5K ﹤0.01% 5937
2017
Q3
$110K Buy
2,967
+380
+15% +$14K ﹤0.01% 5494
2017
Q2
$98K Sell
2,587
-19,792
-88% -$881K ﹤0.01% 5360
2017
Q1
$1.09M Sell
22,379
-16,114
-42% -$735K ﹤0.01% 3120
2016
Q4
$1.31M Buy
38,493
+16,059
+72% +$570K ﹤0.01% 3426
2016
Q3
$847K Sell
22,434
-3,817
-15% -$144K ﹤0.01% 3405
2016
Q2
$883K Sell
26,251
-28,220
-52% -$995K ﹤0.01% 3080
2016
Q1
$1.73M Buy
54,471
+49,582
+1,014% +$1.62M ﹤0.01% 2674
2015
Q4
$183K Buy
4,889
+1,362
+39% +$51.5K ﹤0.01% 4830
2015
Q3
$134K Sell
3,527
-58,298
-94% -$2.05M ﹤0.01% 4789
2015
Q2
$1.77M Buy
61,825
+10,772
+21% +$300K ﹤0.01% 2643
2015
Q1
$1.43M Buy
51,053
+35,610
+231% +$1M ﹤0.01% 2766
2014
Q4
$427K Buy
15,443
+12,925
+513% +$320K ﹤0.01% 4027
2014
Q3
$56K Sell
2,518
-3,374
-57% -$85.7K ﹤0.01% 5238
2014
Q2
$171K Buy
5,892
+1,115
+23% +$29.8K ﹤0.01% 4262
2014
Q1
$136K Sell
4,777
-21,476
-82% -$711K ﹤0.01% 4705
2013
Q4
$1.01M Buy
26,253
+14,117
+116% +$505K ﹤0.01% 3165
2013
Q3
$406K Sell
12,136
-16,943
-58% -$540K ﹤0.01% 3606
2013
Q2
$894K Buy
+29,079
New +$973K ﹤0.01% 2984

Other funds holding MDCO

Citigroup's MDCO Position: Q1 2020 in Review

Citigroup sold out of Medicines Co (MDCO) in Q1 2020, closing a stake of 2,541,983 shares — an estimated $216M sold.

Citigroup first reported a position in MDCO in Q2 2013 and held it in 27 quarters. The position peaked at $216M in Q4 2019. 1 fund tracked by Wall St. Rank holds MDCO as of Q1 2020.

  • Citigroup reported no remaining Medicines Co position as of Q1 2020 after selling out during the quarter.
  • Citigroup sold 2,541,983 Medicines Co shares in Q1 2020, an estimated $216M.
  • Citigroup first reported a position in Medicines Co in Q2 2013 and held it in 27 quarters.
  • Citigroup's Medicines Co position peaked at $216M in Q4 2019.
  • 1 fund tracked by Wall St. Rank held Medicines Co as of Q1 2020.

Based on Citigroup's 13F filing for Q1 2020, filed 12 May 2020.